Search the Newsreel

Praxis Precision Medicines (PRAX) Earnings Date and Reports 2026

Praxis Precision earnings on deck as commercialization nears

Praxis Precision Medicines Inc. is set to report second-quarter results, with investors focused on cash burn and commercial readiness as the company awaits two key FDA drug approval decisions. Analysts have a strong buy rating with significant upside potential. The company's cash runway and …

29 New Praxis Employees Get Stock Units, Four-Year Vesting

Praxis Precision Medicines (PRAX) announced the grant of restricted stock unit (RSU) awards covering 7,318 common shares to 29 new non-executive employees. These inducement grants, made under the 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4), will vest in four equal annual installments, contingent …

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines, Inc. announced that its Compensation Committee granted restricted stock unit awards covering 7,318 shares to 29 new non-executive employees on August 3, 2026. These grants were made under the company's 2024 Inducement Plan as material inducements for employment, in accordance with …

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Consensus Rating of "Moderate Buy" by Brokerages

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $18.00, significantly higher than its current price of $6.40. Despite the positive analyst sentiment, the company remains unprofitable, reporting a quarterly loss of $0.23 …

Responsive Playbooks and the PRAX Inflection

This article analyzes Praxis Precision Medicines Inc. (NASDAQ: PRAX), highlighting weak near and mid-term sentiment that contrasts with a positive long-term outlook. The report identifies no clear price positioning signals and notes elevated downside risk. It also provides three AI-generated trading strategies—Position, Momentum Breakout, …

Bloom Burton Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $14

Bloom Burton has reiterated its Buy rating for Eupraxia Pharmaceuticals (EPRX.US) and maintained its target price at $14. This indicates continued confidence in the company's prospects by the investment firm.

276,000 Shares in Eupraxia Pharmaceuticals Inc. $EPRX Acquired by DV Trading LLC

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Recommendation of "Moderate Buy" by Analysts

Praxis Precision Medicines (PRAX) Projected to Announce Earnings on Monday

Praxis Precision Medicines Inc (PRAX) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Praxis Precision Medicines Inc (PRAX), which currently holds a financial score of 6.42, ranking 245 out of 384 in the Biotechnology & Medical Research industry. The company's financial status is stable with low operating efficiency. Key financial …

Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Praxis Precision Medicines, Inc. announced it will release its second-quarter financial results for the period ended June 30, 2026, and provide a corporate update on Thursday, August 6, 2026, before market open. The company will host a conference call and live webcast at 8:30 …

Praxis will webcast its second-quarter update Aug. 6 at 8:30 a.m.

Praxis Precision Medicines (NASDAQ: PRAX) announced it will report its Q2 2026 financial results and provide a corporate update on Thursday, August 6, 2026, before markets open. The company will host a conference call and live webcast at 8:30 a.m. ET on the same …

Praxis Precision Medicines Inc (PRAX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Praxis Precision Medicines Inc (PRAX), noting its current risk score of 2.04, which ranks it 242 out of 384 in the Biotechnology & Medical Research industry. The company's beta value of 2.75 indicates higher volatility compared to …

PRAX Reiterated by BTIG -- Price Target Maintained at $810

BTIG analyst Kambiz Yazdi reiterated a "Buy" rating for Praxis Precision Medicine (PRAX) and maintained an $810 price target despite the stock showing significant overvaluation at a 1114.8% premium to its GF Value™. The stock's GF Score™ of 38/100 highlights concerns in profitability and …

Ally Bridge Group NY LLC Raises Stock Holdings in Eupraxia Pharmaceuticals Inc. $EPRX

PRAX|Praxis Precision Medicines Inc|Price:293.038|Chg%:-2.772

This article provides a comprehensive stock analysis of Praxis Precision Medicines Inc (PRAX), highlighting its relatively healthy fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite a recent weak stock market performance, the company shows strong fundamentals and …

Praxis Precision Medicines Inc (PRAX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of Praxis Precision Medicines Inc.'s (PRAX) shareholder structure, detailing major shareholders, institutional holdings, and related ETF investments. Key shareholders include Janus Henderson Investors and Perceptive Advisors LLC, with significant institutional ownership changes over recent quarters. The data covers shareholder …

Praxis Precision Medicines Inc (PRAX) Institutional Confidence

Praxis Precision Medicines Inc (PRAX) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. Institutional ownership stands at 114.11%, an increase of 24.71% quarter-over-quarter, with Steven Cohen being the largest individual institutional shareholder. Major institutional holders …

Orbimed Advisors LLC Raises Position in Praxis Precision Medicines, Inc. $PRAX

Orbimed Advisors LLC significantly increased its stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) by 82.5% in the first quarter, now holding 172,500 shares valued at $55.6 million. The company reported a smaller-than-expected quarterly loss of $3.20 per share, surpassing analyst projections of a $3.58 …

SummitTX Capital L.P. Sells 4,791 Shares of Praxis Precision Medicines, Inc. $PRAX

SummitTX Capital L.P. decreased its stake in Praxis Precision Medicines (NASDAQ:PRAX) by 11.5% in the first quarter, selling 4,791 shares and retaining 36,838 shares valued at $11.9 million. Despite this, institutional investors and hedge funds own 67.84% of the company, with notable increases from …

Praxis Home Retail accepts resignation of Anou Singhvi as independent director

Praxis Precision Medicines Inc (PRAX) Balance Sheet - Tradingkey.com

This article from TradingKey.com provides a detailed balance sheet analysis for Praxis Precision Medicines Inc (PRAX), including quarterly and annual financial statements. It covers key metrics such as cash and short-term investments, total assets, liabilities, and shareholders' equity. The data allows investors to evaluate …

TradingKey

This page provides the quarterly and annual income statement for Praxis Precision Medicines Inc. (PRAX), detailing financial performance metrics such as total revenue, operating expenses, operating profit, net non-operating interest income, income before tax, and net income. It also includes frequently asked questions about …

Swiss National Bank Acquires 6,200 Shares of Praxis Precision Medicines, Inc. $PRAX

The Swiss National Bank increased its stake in Praxis Precision Medicines (NASDAQ:PRAX) by 15.3% in the first quarter, purchasing an additional 6,200 shares to bring its total holding to 46,700 shares valued at approximately $15 million. This move comes as other institutional investors have …

Allspring Global Investments Holdings LLC Grows Stake in Praxis Precision Medicines, Inc. $PRAX

Allspring Global Investments Holdings LLC significantly increased its stake in Praxis Precision Medicines, Inc. ($PRAX) by 392.8% in the first quarter of 2026, bringing their total holdings to 8,536 shares valued at $2,725,000. Other institutional investors also adjusted their positions in the company. Analysts …

Praxis Precision Medicines, Inc. Revenue Breakdown – NASDAQ:PRAX

PRAX|Praxis Precision Medicines Inc|Price:325.300|Chg%:+2.900

Praxis Precision Medicines Inc (PRAX) is a clinical-stage biopharmaceutical company focused on central nervous system disorders, with its stock currently trading at $325.30. The company has strong fundamentals and high growth potential, evidenced by high institutional ownership and multiple "Buy" ratings from analysts with …

Understanding the Setup: (PRAX) and Scalable Risk

This article analyzes Praxis Precision Medicines Inc. (NASDAQ: PRAX), highlighting divergent sentiment across different time horizons and suggesting choppy market conditions. It identifies an exceptional 85.2:1 risk-reward setup targeting a 24.6% gain against a 0.3% risk. The analysis provides specific trading strategies (Position, Momentum …

Praxis Precision Medicines (PRAX) Bank of America Global Healthcare Conference 2026 summary

Praxis Precision Medicines presented at the Bank of America Global Healthcare Conference 2026, outlining its strategy to manage a royalty portfolio of over 100 assets, with a focus on late-stage clinical and commercial assets. The company aims for 20% annual growth from its commercial …

PRAX stock trades around recent lows as Praxis Precision Medicines updates pipeline and cash runway

Praxis Precision Medicines Inc. (PRAX) is a clinical-stage neuroscience company whose stock is trading near recent lows due to ongoing clinical and financing risks. The company reported a substantial operating loss and a cash runway into early 2026 based on its 2024 financials, with …

Praxis Precision Medicines (PRAX) Could Be 49% Undervalued As Patch Deal Expands Ulixacaltamide Reach

Should Praxis–Remagine Transdermal Patch Collaboration and FDA Review Extension Reshape PRAX Pipeline Expectations?

Praxis Precision Medicines' collaboration with Remagine Labs to develop a transdermal patch for ulixacaltamide and the FDA's three-month extension for relutrigine's NDA review are significant developments for the company. These events could positively influence the perception of Praxis's pipeline durability and reach, particularly for …

EPRX Forecast — Price Target — Prediction for 2027

Praxis Precision Medicines Stock Surges 27%, With A 6-Day Winning Spree

Eupraxia Pharmaceuticals (EPRX) Slips 2.19% as Stock Tests Key Support at $5.94 - Cumulative Volume